Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab Maintenance Following Allogeneic HCT for ALL
NCT02807883Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2016
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With Toxicities. Started Aug 2016; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02807883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02807883.